MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition. by Ortiz-Zapater, Elena et al.
RESEARCH ARTICLE
MET-EGFR dimerization in lung
adenocarcinoma is dependent on EGFR
mtations and altered by MET kinase inhibition
Elena Ortiz-Zapater1☯*, Richard W. Lee1☯, William Owen1, Gregory Weitsman2,
Gilbert Fruhwirth3, Robert G. Dunn4, Michael J. Neat4, Frank McCaughan1, Peter Parker5,6,
Tony Ng2,5,7,8, George Santis1*
1 Division of Asthma, Allergy and Lung Biology, King’s College London, Guy’s Hospital, London, United
Kingdom, 2 Richard Dimbleby Department of Cancer Research, Randall Division of Cell and Molecular
Biophysics, King’s College London, Guy’s Medical School Campus, London, United Kingdom, 3 Department
of Imaging Chemistry and Biology, Division of Imaging Science and Biomedical Engineering, King’s College
London, The Rayne Institute/St. Thomas’ Hospital, London, United Kingdom, 4 Department of Cancer
Genetics, Viapath, Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital, London, United Kingdom,
5 Division of Cancer Studies, King’s College London, Guy’s Medical School Campus, London, United
Kingdom, 6 Protein Phosphorylation Laboratory, Francis Crick Institute, London, United Kingdom, 7 Breast
Cancer Research Unit, King’s College London, Guy’s Hospital, London, United Kingdom, 8 UCL Cancer
Institute, Paul O’ Gorman Building, University College London, London, United Kingdom
☯ These authors contributed equally to this work.
* elena.ortiz-zapater@kcl.ac.uk (EOZ); george.santis@kcl.ac.uk (GS)
Abstract
Advanced lung cancer has poor survival with few therapies. EGFR tyrosine kinase inhibitors
(TKIs) have high response rates in patients with activating EGFR mutations, but acquired
resistance is inevitable. Acquisition of the EGFR T790M mutation causes over 50% of resis-
tance; MET amplification is also common. Preclinical data suggest synergy between MET
and EGFR inhibitors. We hypothesized that EGFR-MET dimerization determines response
to MET inhibition, depending on EGFR mutation status, independently of MET copy num-
ber. We tested this hypothesis by generating isogenic cell lines from NCI-H1975 cells, which
co-express L858R and T790M EGFR mutations, namely H1975L858R/T790M (EGFR TKI
resistant); H1975L858R (sensitized) and H1975WT (wild-type). We assessed cell proliferation
in vitro and tumor growth/stroma formation in derived xenograft models in response to a
MET TKI (SGX523) and correlated with EGFR-MET dimerization assessed by Fo¨rster Res-
onance Energy Transfer (FRET). SGX523 significantly reduced H1975L858R/T790M cell
proliferation, xenograft tumor growth and decreased ERK phosphorylation. The same was
not seen in H1975L858R or H1975WT cells. SGX523 only reduced stroma formation in
H1975L858R. SGX523 reduced EGFR-MET dimerization in H1975L858R/T790M but induced
dimer formation in H1975L858R with no effect in H1975WT. Our data suggests that MET inhi-
bition by SGX523 and EGFR-MET heterodimerisation are determined by EGFR genotype.
As tumor behaviour is modulated by this interaction, this could determine treatment efficacy.
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Introduction
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have revo-
lutionised treatment of non-small cell lung cancer (NSCLC) in patients with EGFR mutations.
These mutations cause constitutive kinase activity and are oncogenic drivers in 10–20% of
Caucasian patients and up to 50% of eastern Asians.[1] Such mutations induce conformational
changes in the receptor that alter the dimerization interface, destabilize the inactive state and
increase kinase activity to 50 times that of the wild type (WT) EGFR.[2] The EGFR exon 21
L858R and in-frame exon 19 deletions account for 85% of such mutations.[3] Whilst responses
are often impressive, resistance is inevitable. The commonest mechanism for resistance is
acquisition or clonal expansion of the EGFR exon 20 T790M mutation.
Amplification of the MET receptor represents an important alternative resistance mecha-
nism [4, 5, 6, 7]. MET is a high affinity tyrosine kinase receptor for hepatocyte growth factor
(HGF).[8] Derailment of normal MET signaling is associated with invasive growth, tumor pro-
gression and metastases; [9] aberrant MET signaling can result from MET over-expression,
amplification or mutations, all of which are relevant in NSCLC.[4, 5, 6, 7] MET amplification
predicts worse survival in NSCLC, [10] it has been implicated in 5–20% of patients with
acquired resistance to EGFR TKI [11, 12, 13, 14] and correlates with response to MET inhibi-
tor therapy [13]. Blockade of MET is a therapeutic strategy in EGFR TKI resistance. The most
advanced agents, METMAb, a MET neutralizing antibody and Tivantinib, a small molecule
inhibitor of MET have both failed in phase III clinical trials [15]; despite this, there is consider-
able interest in the therapeutic potential of MET inhibition in NSCLC. In fact, Crizotinib, a
MET proto-oncogene, receptor tyrosine kinase (MET) tyrosine kinase inhibitor (TKI) is cur-
rently in clinical trial showing good results for both MET amplification and MET exon 14
skipping [14].
MET may exert its oncogenic effects through crosstalk with other membrane receptors
including the EGFR family, as evidenced by MET and EGFR co-expression in lung cancer cell
lines, [16] crosstalk between EGFR and MET signaling pathways and direct co-immunopre-
cipitation.[16, 17, 18] Moreover, MET amplification in association with EGFR mutations
additionally has a worse clinical prognosis than EGFR mutations alone.[10] In light of these
observations, we sought to understand the importance of EGFR and MET interaction and we
have hypothesized that the efficacy of MET inhibition can be influenced by EGFR mutation
status. We explored this hypothesis by evaluating the response of three lung adenocarcinoma
cell lines that differ only in their EGFR genotype to the MET inhibitor SGX523 in vitro and in
a murine xenograft model derived from the same cells. Our data suggest that EGFR mutations
can determine the effect of MET inhibition independently of MET copy number, by changing
EGFR-MET dimerisation. As tumor behaviour is modulated by this interaction, this could
determine treatment efficacy.
Results
EGFR-MET interaction is modulated by EGFR mutations
To assess if EGFR-MET interaction is modified by EGFR mutations, we first generated two
novel cell lines by modification of the NCI-H1975 lung adenocarcinoma cell line that harbours
L858R and T790M (L858R/T790M) mutant EGFR (to be referred to from here on as
H1975L858R/T790M). We used lentiviral shRNA knockdown of EGFR (targeting the 5’ UTR of
EGFR) in the H1975L858R/T790M, followed by transfection with a plasmid encoding wild/type
(wt) EGFR and EGFR with the L858R mutation, to generate the H1975WT and the H1975L858R
cell lines respectively. Relative allele frequency (L858R vs. T790M) in these cell lines was
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quantified by digital droplet PCR. We observed equal L858R and T790M copies in the
H1975L858R/T790M cells and a clear reduction of L858R and T790M EGFR alleles in the
H1975WT cells, confirming their effective knockdown following shEGFR treatment; we also
observed decrease of the EGFR-T790M allele frequency in the H1975L858R cells (Fig 1A).
Using Western blot (WB), we showed the total levels of EGFR in the generated cell lines (Fig
1B) and that the H1975L858R and H1975WT cells became sensitive to the EGFR TKI Erlotinib
Fig 1. In vitro validation of the H1975 EGFR mutant cell lines. (A) Relative mutant allele frequency was compared in cDNA from each
cell line by Digital droplet PCR. (B) WB of total EGFR levels in the H1975L858R/T790M cell line before and after lentivirus infection with a
shEGFR and in the H1975 cell lines. hsc70 levels are shown as loading control. Values beneath blots are relative levels of T-EGFR
compared to the H1975L858R/T790M cell line from 2 independent experiments (C) WB of phospho and total EGFR in H1975 derivative cell
lines untreated or treated with EGF (100ng/mL) for 15 min, Erlotinib (1μM, 5μM or 10 μM) for 1 hour or both. hsc70 levels were used as
loading control. Quantification of the WB is shown above the figure from 3 independent experiments. Error bars is SD (*p<0.05 and
**p<0.001).
doi:10.1371/journal.pone.0170798.g001
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upon removal of the T790M EGFR sequence even at a low concentration of Erlotinib (Fig 1C).
Introduction of a GFP plasmid in the H1975L858R/T790M cell line didn’t affect the Erlotinib
resistance (Fig A in S1 File).
We then explored the interaction between EGFR and MET in the cells lines studied. We
observed no differences in basal MET protein levels between the cell lines (Fig 2A). Given that
MET expression is not a good marker for MET activation we also treated the three cell lines
with HGF for different times to asses for the phospho-MET levels. We could observe no differ-
ence in the activity of MET in the different cell lines (Fig B in S1 File). As MET amplification
has been implicated as a mechanism by which secondary resistance EGFR TKI can emerge in
NSCLC, we used a MET/cep7 fluorescence in situ hybridization (FISH) probe and calculated
the ratio of MET to chromosome 7 centromere signals and the mean copy number of MET.
The MET/cep7 ratio was <1 in all three cell lines; however, MET copy number was increased
in all (Fig 2B).
Immunofluorescence staining and confocal images showed that both proteins co-localise
similarly in the membrane of the three cell types (Fig 2C). Immunoprecipitation result showed
there was more interaction between EGFR and MET in H1975L858R/T790M compared to
H1975L858R and H1975WT cells (Fig 2D), which provides evidence of potential differential
interaction between MET and different EGFR mutant types. Since a direct protein interaction
(nanometer (nm) proximity) between MET and EGFR cannot be inferred by these experi-
ments, we assessed Fo¨rster Resonance Energy Transfer (FRET) using fluorescence lifetime
imaging microscopy (FLIM) which is the gold standard technique for measuring protein
proximity within the typically <10nm range [19, 20, 21, 22]. Results show that highest FRET
efficiency between MET and EGFR occurred in H1975L858R/T790M cells, in contrast with signif-
icantly lower FRET efficiency in the H1975L858R and H1975WT cells (Fig 2E). These results
demonstrate that EGFR and MET can interact directly at the cell membrane and that the
level of interaction is significantly higher in H1975L858R/T790M compared to H1975L858R and
H1975WT cells.
Inhibition of MET changes the EGFR-MET interaction both in vitro and in
vivo
In view of the observed differences in the interaction between EGFR and MET in our cells, we
hypothesised that MET inhibition would also result in different outcomes. To test this, we
used SGX523, a selective MET kinase inhibitor.[23] After confirming rapid (15min) and sus-
tained (48hr) SGX523 inhibition of MET phosphorylation in the three cell lines (Fig C in S1
File), we measured change in the interaction between MET and EGFR using FRET before and
after MET inhibition by SGX523. We found that the interaction between MET and EGFR in
H1975L858R/T790M cells was significantly reduced in the presence of SGX523. By contrast,
SGX523 led to a significant increase in MET-EGFR interaction compared to baseline in
H1975L858R cells (Fig 3A and 3B). There was no significant difference in the FRET between
MET and EGFR before and after MET inhibition in the H1975WT cells. These results provide
evidence to support the hypothesis that MET inhibition by SGX523 altered the direct interac-
tion between MET and EGFR in a mutation-specific manner in these cells.
To test whether the differential effects of SGX523 on MET and EGFR interaction could be
reproduced in vivo, we generated a xenograft model using the H1975-derived mutant cell
lines. H1975L858R/T790M, H1975L858R and H1975WT cells were injected into the flanks of BalbC
mice and tumors were allowed to grow for 2 weeks. Mice were then subjected to 12 days of
treatment with SGX523 or vehicle administered daily by oral gavage. Tumor volumes were
measured every two days until animals were culled and tissue collected (see Fig 4D). WB and
MET-EGFR Dimerization in Lung Cancer
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Fig 2. EGFR-MET interaction is modulated by EGFR mutations. (A) Western blot (WB) of total MET levels in
H1975 derived cells. Tubulin levels are shown as loading control. Values beneath blots are relative levels of MET
compared to the total levels in the H1975L858R/T790M cell line from 2 independent experiments +/−SD (B) MET (7q31)
(red signal) copy number analysis by FISH in the three H1975 cell lines using the Leica Kreatech C-MET (7q31)/SE7
FISH probe (KBI-10719). The green signal indicates the chromosome 7 centromere control probe. Scale bar 10 mm.
Average copy number and ratio between MET and chromosome 7 centromere probe are also indicated (n = 30
cells). (C) Immunofluorescence of total EGFR (Alexa546 –red in the image) and MET (Cyanine 5 –green in the
MET-EGFR Dimerization in Lung Cancer
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immunohistochemistry (IHC) (Fig D (i) and (ii) in S1 File) confirmed target tissue drug
delivery.
We observed the highest FRET between MET and EGFR in H1975L858R/T790M derived
tumors, and this was again significantly reduced by SGX523 (Fig 3C and 3D). In H1975L858R
derived tumors, MET-EGFR interaction at baseline was low and increased significantly by
SGX523. There was no significant change in FRET between MET and EGFR in xenograft tis-
sue derived from H1975WT cells. These results mirror the in-vitro findings with these cells (Fig
3C and 3D). We conclude that MET interacts with EGFR differently in cells that encode WT,
L858R and L858R/T790M-EGFR and SGX523 modifies this interaction in opposite directions
in L858R and L858R/T790M-EGFR encoding cells in vitro and in vivo.
In vitro and in vivo effects of MET inhibition on cell proliferation
In order to assess functional consequence of MET kinase inhibition, we assessed the prolifera-
tion rate of the generated cells before and after MET inhibition. We found that the H1975L858R
cells were more proliferative than the H1975L858R/T790M or H1975WT cells (Fig E (i) and (ii) in
S1 File). MET inhibition significantly decreased proliferation rate in H1975L858R/T790M cells
only (Fig 4A and 4B). We also assessed proliferation in a 3D environment using an anchorage
independent growth assay. As expected, we found that the H1975L858R cells produced most
colonies (Fig E (iii) in S1 File). In the presence of SGX523, there was a significant decrease in
the number of large colonies in H1975L858R/T790M cells. SGX523 had no effect in the 2D or 3D
proliferation rate in the case of the H1975WT cells or in the H1975L858R cells (Fig 4C).
We then analysed the in vivo effect of oral administration of SGX523 on tumor growth and
proliferation. As was the case in vitro, the H1975L858R was the most proliferative cell line in
vivo (Fig 4D and Fig F (i) in S1 File). The H1975L858R/T790M-derived tumors in SGX523 treated
mice grew more slowly than in vehicle treated mice; this effect was evident after 4 days of
SGX523 administration and was sustained up to 14 days. SGX523 had no effect in the prolifer-
ation in the H1975L858R and H1975WT derived tumors over the 14-day growth period (Fig
4D). This result was confirmed using the proliferation marker phospho-Histone H3 (Fig 4E).
In vitro and in vivo effects of MET inhibition on stroma remodeling
We observed marked morphological differences in the xenograft tumors derived from the dif-
ferent cell lines. H1975L858R/T790M-derived tumors were dense and cellular with tightly packed
cells oriented in similar directions. The H1975L858R-derived tumors had abundant intra-
tumoral stromal tissue deposition leading to highly segregated cells that appeared to grow by
interaction with the stroma (Fig F (ii) in S1 File). Given this different tumours appearance, as
well as the important role proposed for MET in tumour-tissue interaction and in cell migra-
tion/metastasis, we analysed stromal compartment markers, namely collagen deposition
(Masson’s trichrome), anti-smooth muscle actin staining (α-SMA), a marker of activated
fibroblasts and cd31 staining to assess for neovascularization, before and after SGX523 treat-
ment. The H1975L858R-derived tumors demonstrated the most substantial collagen deposition
image) in H1975 derived cells. Hoescht dye was used to stain the nuclei of the cells. Merge panels are also shown.
Bars, 20 μm. (D) Co-immunoprecipitation (IP) of EGFR in H1975 derived cell lines. The EGFR antibody was used to
immunoprecipitate. EGFR and MET levels are shown in both bound and input fractions. The gels shown in the figure
were run separately for the bound and input fractions, as indicated by the dotted line, under the same experimental
conditions. (E) Fluorescence lifetime imaging was performed on cells plated to sub-confluence on cover-slips and
time-resolved analysis in Tri2. Quantification of average FRET efficiency (*** p < 0.0005) is shown, as well as
representative pseudocolour lifetime images showing FRET efficiency and corresponding grayscale donor
(EGFR-Alexa 546) and acceptor (MET-Cyanine 5) intensity images. Scale bar: 50μm.
doi:10.1371/journal.pone.0170798.g002
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Fig 3. Inhibition of MET changes the EGFR-MET interaction both in vitro and in vivo. (A) Fluorescence
lifetime imaging performed in the three H1975 cell lines plated on coverslips with or without treatment with
SGX523 (5 μM) for 24 hours. Representative pseudocolour lifetime images showing FRET efficiency
accompanied by corresponding grayscale donor (EGFR-Alexa 546) and acceptor (MET-Cyanine 5) intensity
images are shown. Scale bar: 50μm. (B) Bar graph showing quantification for average FRET efficiency in the
three cell lines with or without SGX523 treatment (*** p < 0.0005, ** p = 0.001). (C) Quantification of average
FRET of EGFR-MET interaction performed in xenograft tumors from each H1975 cell line in mice receiving
mock or SGX523 treatment (60 mg/kg) for 12 days (*** p<0.001, * p<0.05). (D) Representative lifetime
images for EGFR:MET FRET in xenograft tumors accompanied by corresponding grayscale donor
(EGFR-Alexa 546) and acceptor (MET-Cyanine 5) intensity images. Scale bar, 50μm.
doi:10.1371/journal.pone.0170798.g003
MET-EGFR Dimerization in Lung Cancer
PLOS ONE | DOI:10.1371/journal.pone.0170798 January 31, 2017 7 / 19
Fig 4. In vitro and in vivo effects of MET inhibition on cell proliferation. (A) Representative images of the three
cell lines grown at 60% confluence on coverslips and treated or not with SGX523 (5 μM) for 24 hours. Scale bar,
20μm. The BrdU positive nuclei (red) show the cycling cells, and the Hoechst dye was used to stain all the nuclei of
the cells (in blue). (B) Quantification of the proliferation rates as described in (A) (*p <0.04, **p<0.005,
***p<0.0001). (C) Soft agar colony formation in the H1975 derivate cell lines. The graph shows the number of
colonies after 3 weeks of growing in the presence or absence of SGX523 (5 μM) (*p <0.001). Representative
images of untreated and SGX523 treated colonies are also shown. (D) Graphs showing the fold change in volumes
in 16 xenografts tumors (8 coming from mice subjected to vehicle and 8 from SGX523 treatment) coming from the
three H1975 cell lines during the 12 days of treatment. Tumor volumes were measured at the indicated times using a
MET-EGFR Dimerization in Lung Cancer
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and α-SMA staining (Fig F (iii) in S1 File). We also found that H1975WT and H1975L858R-
derived-tumors showed more angiogenesis than the H1975L858R/T790M-derived tumors (Fig F
(iii) in S1 File). When we compared the untreated vs. the SGX523 treated tumors, we observed
significant reduction in collagen (MT) (Fig 5A), α-SMA (Fig 5B) and cd31 (Fig 5C) staining in
the H1975L858R. SGX523 had no effect on these parameters in H1975L858R/T790M and H1975WT
derived tumors.
These results suggest a paracrine response to MET inhibition only in H1975L858R cells. We
dismiss a different autocrine response, as EGF and HGF secreted by the three cell lines was
similar (Fig 5D).
In vitro and in vivo effects of MET inhibition on ERK, AKT and FAK
phosphorylation
We finally investigated whether there were also differential effects of MET kinase inhibition
on signaling pathways. We treated H1975L858R/T790M, H1975L858R and H1975WT cells with
SGX523 for 24 hours. Phosphorylation of MET was inhibited but we saw no change in the
phosphorylation of EGFR with the SGX523 treatment. We then assessed phosphorylation lev-
els of ERK, AKT and FAK after SGX523. The only significant finding from these studies was a
reduction in ERK phosphorylation in SGX523 treated H1975L858R/T790M cells (Fig 6A and 6C).
We repeated these experiments in the presence of EGF and or HGF in the cells treated or not
with SGX523 to better understand the decrease in the stromal markers in the H1975L858R but
we observed no effect in the phosphorylation of AKT or FAK (Fig G in S1 File). Finally, the
analysis of xenograft tumors obtained from SGX523 or vehicle treated animals also showed
reduction in phosphorylated ERK in H1975L858R/T790M-derived xenografts (Fig 6B and 6C).
These observations provide potential explanation for our observation that SGX523 had anti-
proliferative effect in H1975L858R/T790M-derived tumors but not H1975L858R and H1975WT
cells and tumors.
Discussion
In this study we have demonstrated that the responses to MET inhibition in an in vitro and in
vivo lung cancer model differed depending on the EGFR genotype. Using as a starting point
the H1975 lung adenocarcinoma cell line that harbours double mutated (L858R/T790M dou-
ble mutant) EGFR, we have developed a cellular model to minimise the contribution of con-
founding influences. Using Droplet PCR, WB and EGFR TKI sensitivity, we established that in
each line the dominant EGFR genotype was of greatest functional importance. We considered
the merits of a CRISPR approach to achieve purer cell populations. However, the validation
steps described and the tumour cell heterogeneity inherent to our approach could offer a good
reflection of the clinical situation.
Our key novel finding from in vitro and in vivo studies is that MET inhibition by SGX523
reduced proliferation and tumor growth in the H1975L858R/T790M cells and inhibited indices of
stromal deposition in H1975L858R cells. MET inhibition in H1975L858R/T790M cells also sup-
pressed ERK signaling consistent with interference with an autocrine signaling loop. Con-
versely, in H1975L858R cells the effects of SGX523 behavior was more consistent with a
paracrine activity of the MET receptor (see Fig 5D). These variations in SGX523 responses in
calliper and calculated in based of the equation 0.4xAxB^2 (A, the long axis and B, the short axis of the tumor). (E)
Quantification of phospho-histone H3 (P-H3) staining in the xenograft derived tissue in the presence or absence of
SGX523 (**p<0.05) Representative images are also shown. Bar, 250 nm.
doi:10.1371/journal.pone.0170798.g004
MET-EGFR Dimerization in Lung Cancer
PLOS ONE | DOI:10.1371/journal.pone.0170798 January 31, 2017 9 / 19
Fig 5. In vitro and in vivo effects of MET inhibition on stroma remodeling. Quantification and representative images of (A) collagen,
(B) α-SMA and (C) cd31 staining of xenografts tumors (FFPE) grown from each H1975 derivate cell line coming from mice treated or not
(mock) with SGX523 (60 mg/kg). Bar 250 nm. Quantification of the staining is shown above the images and was performed using Image
J. (*p<0.05, **p<0.01, ***p<0.001). EGF (D) and HGF (E) quantification assessed by ELISA in each H1975 derivate cell line
supernatants.
doi:10.1371/journal.pone.0170798.g005
MET-EGFR Dimerization in Lung Cancer
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Fig 6. In vitro and in vivo effects of MET inhibition on ERK, AKT and FAK phosphorylation. (A) WB of
phospho- and total EGFR, MET, AKT, ERK and FAK from cell lysates of the different H1975 cell lines treated or not
with SGX523 (5 μM) for 24 hours. Gels shown are representative of three experiments, and were run separately for
each cell line, as indicated by the dotted line, under the same experimental conditions. Hsc70 levels are also shown
as loading control. Values beneath blots are relative levels of each phospho vs total protein comparing the untreated
(UT) and the SGX523 treated conditions for each cell line for 3 independent experiments and for 2 independent
experiments in the case of the P-FAK/FAK +/−SD (*p<0.05, **p<0.001) (B) WB of phospho- and total-ERK in the
extracts coming from the H1975L858R/T790M-derived xenografts tumors in vehicle (mock) and SGX523 treated mice.
MET-EGFR Dimerization in Lung Cancer
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each cell line led us to hypothesize that these differences could be in part a product of the inter-
action between the EGFR and MET.
Existing evidence supports EGFR-MET crosstalk. Our own data showing co-localization
and co-immunoprecipitation of EGFR and MET at the cell membrane is in agreement with
these observations. Importantly, receptor dimerisation is essential for both MET and EGFR
signaling and intracellular effect. EGFR can dimerise with itself and other members of the
HER family. Previous studies have shown that cell proliferation and tumorigenesis are
enhanced in tumor xenografts co-expressing HER family heterodimers compared to those
expressing single receptors.[24] For example, the well-characterized HER2-HER3 pair is the
most oncogenic in breast cancer.[25] It has also been suggested that MET can interact not only
with EGFR but with other proteins that drive receptor activation, such as integrins, [26] plexin
B1, [27] and CD44v6.[28] The relevance of any such interactions in the context of different
EGFR genotypes and in response to MET inhibition has not been explored.
To the best of our knowledge ours is the first study to utilise FRET FLIM imaging to dem-
onstrate EGFR-MET direct dimerisation. Importantly, we observed that the FRET between
EGFR and MET differed according to EGFR genotype, providing a potential novel mechanism
by which responses to MET inhibition can differ. In H1975L858R/T790M cells, SGX523 reduced
EGFR-MET FRET. Conversely FRET was increased by SGX523 in H1975L858R cells but had no
significant effect on FRET in H1975WT cells. SGX523 is known to preferentially bind the less
active, unphosphorylated form of MET.[23] Therefore, the differences observed suggest that
EGFRL858R/T790M favours the phosphorylated form of MET; by contrast, EGFRL858R only
dimerised with MET in the presence of SGX523, which suggests the opposite. No such modu-
lation was seen in H1975WT suggesting that the altered binding by MET in its active or inactive
form was related to the presence of mutated and not WT-EGFR. Altered dimerisation between
MET and mutant EGFR in EGFRL858R/T790M and H1975L858R cells in the presence of SGX523
could be explained by SGX523-induced conformational changes; such conformational changes
following treatment with small molecule kinase inhibitors are recognized and can be associ-
ated with unexpected responses to treatment. For example HER2-HER3 dimer formation
occurs in breast cancer following treatment with Lapatinib.[29] Our studies cannot discrimi-
nate between the binding of MET with an EGFR monomer or homodimer. Dimer formation
may activate one or other of the receptors or indeed both. In the case of higher order oligo-
mers, MET may facilitate or impede EGFR homodimer formation or modulate the kinase
activity of EGFR molecules within the homodimer. EGFR remained phosphorylated after
treatment with SGX523 (Fig 5A). Whether MET is additionally capable of phosphorylating
EGFR or modulating EGFR activity allosterically is not clear.
We observed clear phenotypic differences between the three cell lines. This may result from
different tendency to activation or affinity for substrate. For example L858R and L858R/
T790M have increased ligand-activated signaling activity compared with WT-EGFR, particu-
larly with respect to downstream effectors involved in cell survival and activation of transcrip-
tion.[30] This is in agreement with published work showing that the EGFR mutants mediate
significantly increased ligand-independent activation of the receptor.[31] This could explain
that the presence of EGFR L858R mutant increases proliferation in the cells and tumors, and
the novel finding that these cells also produce tumors with higher stromal markers. Alterna-
tively, the EGFR-MET dimer offers a novel interpretation of the differences between the lines.
hsc70 is also shown as loading control. (C) Quantification of the P-ERK vs T-ERK WBs shown in (A) and in (B)
(*p<0.05). (D) Schematic model demonstrating effect of SGX523 on EGFR-MET dimerization pattern and
consequences for tumor characteristics following treatment.
doi:10.1371/journal.pone.0170798.g006
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In the H1975L858R/T790M cells, where the EGFR-MET dimer is present at baseline, downstream
signals may be driven by this heterodimer. The addition of SGX523 resulted in loss of EGFR-
MET heterodimer and reduction in phosphorylated ERK in the H1975L858R/T790M cells and
derived tumours, in agreement with this hypothesis. In the cells expressing EGFR L858R
there is no EGFR-MET dimer at baseline. The addition of SGX523 increases the dimerisation
between the receptors, which resulted in the decrease of stromal markers such as % of collagen,
SMA or cd31 staining, in the absence of inhibition in any of the typical signaling pathways
analysed. However, as previously suggested, the interplay of EGFR with MET could provide a
secondary set of effectors molecules through MET binding sites and furthermore through
other receptors with which MET is reported to interact, such as HER3.[13] It is therefore likely
that additional as yet unidentified pathway is active whilst the AKT/FAK pathway may not
dominate in MET inhibition in this model.
What is the implication of our findings on the potential role of MET inhibition in lung can-
cer? Current emphasis is on the role of MET amplification as biomarker to select patients for
MET inhibitor therapy in both treated or untreated NSCLC.[15, 16, 32, 33, 34]. Our observa-
tions that the effects of MET inhibition are influenced by EGFR-MET dimerisation and in
turn EGFR genotype, suggest novel mechanisms to understand how best to target MET in
NSCLC and highlight the importance of understanding the interaction between multiple
driver mutations when facing treatment resistance. Designing a FRET-FLIM assay that mea-
sures EGFR-MET heterodimerisation could potentially play a role in patient selection for
MET targeted therapy. It is also interesting to speculate how our observations on the effects of
SGX523, a MET kinase inhibitor, may influence treatment options in NSCLC. Whether it
would be preferable in the future to target MET with a monoclonal antibody or through direct
targeting of its kinase domain is unknown. A better understanding of crosstalk between thera-
peutic targets, which could be targeted in parallel, may also be of benefit to treatment efficacy
and cost-effective use.
In summary, we have demonstrated using FRET that we can measure the interaction
between EGFR and MET and we have made the important observation that response to MET
inhibition correlates with EGFR-MET dimerisation, which is influenced by EGFR genotype.
This could result from the different EGFR-MET dimers that arise following treatment with
SGX523. The next important steps will be to determine how this information can be used to
select effective therapies targeting MET.
Materials and methods
Reagents and antibodies
Recombinant Human Epidermal Growth Factor (EGF) and Hepatocyte Growth Factor (HGF)
were purchased from Peprotech. SGX523 was purchased from GE and Erlotinib from Cayman
chemicals; both were solubilised in DMSO. All antibodies (Abs) were purchased from com-
mercial sources as indicated. For tissue and cell staining, Phospho-Histone H3 was from Milli-
pore, α-SMA from AnaSpec Inc., cd31 from Abcam, total cMET (D1C2) from Cell Signaling
Technology and EGFR Ab from Novocastra/Leica. For immunoprecipitation, the EGFR Ab
was from Santa Cruz Biotechnology (sc-120). For Western Blot, phospho-EGFR (Y1173), total
EGFR phospho-MET (Y1234), total MET, phospho-ERK (Thr202/Tyr204), total ERK, pho-
pho-AKT (Ser473), total AKT, phosphor-FAK (Tyr397) and total FAK were from Cell Signal-
ing Technology; tubulin was from Millipore and hsc70 from Santa Cruz Biotechnology. For
proliferation assays, anti-Brdu was purchased from Abcam.
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Plasmid construction
Plasmid encoding non-tagged pcDNA3-EGFR was a kingly gift from Dr. Tai Kiuchi (Tohoku
University, Aoba-ku, Sendai, Miyagi, Japan). For control transfections, pEGFP-N3 vector
from Clontech was used. Plasmid for L858R EGFR mutant was created by site-directed muta-
genesis, using the following forward primer: GTC AAG ATC ACA GAT TTT GGG cgg GCC AAA
CTG CTG GGT GCG and reverse primer: CGC ACC CAG CAG TTT GGC ccg CCC AAA ATC
TGT GAT CTT GAC. The reaction was made using a site-directed mutagenesis kit from Strata-
gene and following manufacturer’s instructions.
Cell lines, cell culture and transfection
All cell lines were cultured at 37˚C and 5% CO2. Phoenix Ampho HEK293T cells were main-
tained in Dulbecco´s modified Eagle medium and the NCI-H1975 cells lines in RPMI-
1640 (Invitrogen), both mediums with 10% fetal bovine serum (FBS, Gibco). To generate
H1975L858R and H1975WT cells, shRNA against 5’ UTR EGFR GFP tagged was obtained from
Sigma (siMission) and used to produce lentiviral particles in HEK293T cell line. Stable cells
expressing shEGFR-GFP were selected with puromycin (1.5 μg/ml) for 5 days. After selection,
pcDNA3 constructs containing WT or L858R EGFR were transfected in the cells with Fugene
HD following manufacturer’s instructions. Selection was performed for 5 days with G418
(50 μg/ml). EGFR total, L858R EGFR, and L858R + T790M EGFR levels were analysed by WB
and Droplet PCR. For experiments requiring growth factor stimulation serum-starved cells
were treated with 100 ng/ml EGF or 250 ng/ml HGF.
Droplet polymerase chain reaction
Cells were plated for confluence and DNA extracted from cells using a DNeasy Blood and Tis-
sue Kit (Qiagen) according to manufacturer’s protocol. Digital Droplet PCR was performed
using reference primers/probe sets validated on the BioRAD QX100 mdPCR system (Biorad)
using commercially available reference standards. Data was analysed using Quantasoft
(Biorad) software. Droplets were scored as positive or negative based on relative fluorescence
intensity in FAM or VIC/HEX channels.
Western blotting (WB)
Cells were lysed in buffer (0.05 M Tris-HCl, 0.15 M NaCl, 1% Triton X-100, pH 7.2), contain-
ing protease and phosphatase inhibitors. After centrifugation, proteins in the supernatant were
quantified, boiled with Laemmli buffer, resolved by SDS-PAGE and transferred to a nitrocellu-
lose membrane. WB was performed using standard procedures.
Immunofluorescence microscopy
Cells cultured on cover slips were fixed using 2% PFA in PBS for 15 min and then permeabi-
lised with 0.25% Triton X-100. After blocking with 1% BSA and 1% FBS in PBS, cells were
incubated with the primary antibodies ON at 4˚C. Cells were then washed and incubated with
secondary antibodies (all from Jackson ImmunoResearch Laboratory). Confocal images were
obtained with an LSM510 microscope (Carl Zeiss) and analysed using LSM Viewer software.
Fluorescence in situ hybridization (FISH)
Cells were plated on coverslips and fixed with Carnoy’s fixative (3:1 methanol to acetic acid).
After washing with PBS, incubation with the MET/cep7 FISH probe was performed for 16
hours at 36˚C after a 5minute denaturation at 72˚C. The coverslips were washed in 0.4xSSC at
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72˚C for 5 minutes, followed by 2 minutes in 4xSSC/Tween and two rounds of 2 minutes in
PBS at room temperature. The coverslips were then mounted onto slides with DAPI counter-
stain and analysed using a fluorescence microscope.
Immunoprecipitation
Cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 10% glycerol, 1% Triton X-100, 10 mM NaF, 1 mM Na3VO4, 10 mM N-ethylmalei-
mide, 0.01 μM Calyculin A) with Protease inhibitor cocktail set I (Roche). After centrifugation,
the supernatants were incubated overnight at 4˚C with anti-EGFR or an irrelevant IgG, and
subsequently for an additional hour with protein A/G-Agarose beads (Alpha Diagnostic Inter-
national Inc.). After centrifugation, the immunoprecipitates were washed and subjected to
SDS-PAGE and analysed by WB.
BrdU incorporation
Cell proliferation was determined by 5’-Bromo-Uridine (BrdU) based assay. Cells were plated
for sub-confluence on coverslips in a 24-well plate and BrdU was added to the cells for 3
hours. Coverslips were then prepared for immunofluorescence staining as described below
with an additional 15 minutes DNA denaturation step using 1.5M Hydrochloric Acid (HCl)
and using a BrdU Ab. Hoechst was used to stain all the cell nuclei. Images were obtained
LSM510 microscope (Carl Zeiss) and quantified in ImageJ using a macro to automate cell
counting for red vs blue nuclei.
Soft-agar growth assay
Anchorage-independent growth was evaluated as described before.[35] Briefly, 1x104 cells
were plated in complete DMEM containing 0.3% soft agar in 6-cm plates over a solidified
DMEM plated in containing 0.7% soft agar layer. Medium was added twice a week to maintain
humidity. After 3 weeks, colonies were stained with crystal violet (0.02%) for 1 hour and
counted.
Wound healing experiments
Cells were seeded to confluence. A horizontal wound was made through the middle of the
wells using a micropipette tip. Cells were allow to migrate (heal the wound) for different times
(0, 2, 8, 20 and 28 hours). Images were taken and the wound closure was quantified using
Image J software analysis.
In vivo tumorigenicity assay
H1975WT, H1975L858R and H1975L858R/T790M cell lines (3x106) were injected subcutaneously
into the two posterior flanks of BALB/c nude mice (Charles River Laboratories). For each cell
line, 16 female 5 weeks old mice were used. Mice were followed weekly and tumors allowed
growing for 13 days after injection. Tumors were measured with a caliper in long and short
axes and volume was determined in based of the equation 0.4xAxB^2 (A, the long axis and B,
the short axis of the tumor). At day 14th after injection mice were divided randomly in two
groups (6 animals/group) and vehicle or SGX523 (drug treatment) was started. 60 mg/kg of
SGX523 (equilibrated suspensions in 0.5% Methocell A4M) was administered for 12 days,
daily, by oral gavage. At day 25th after injection mice were culled using CO2 and tumours
were removed aseptically with dissecting scissors and weighed. All animals were maintained
under specific pathogen-free conditions and handled in accordance with the Institutional
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Committees on Animal Welfare of the UK Home Office (The Home Office Animals Scientific
Procedures Act, 1986). All animal experiments were approved by the Ethical Review Process
Committee at King’s College London and carried out under license from the Home Office,
UK.
Tissue samples, immunohistochemistry and histopathological analysis
Tissue samples obtained from xenografts were fixed with formalin and paraffin-embedded.
Immunohistochemical analyses were performed using 3 μm sections. Briefly, slides were
dewaxed and antigen retrieval was performed using 0.1M citrate pH 6.0 buffer at 120˚C for 10
min, followed by blocking in TBS-Tween 0.1% + 1% BSA + 1% FBS. Primary antibodies were
added overnight at 4˚C. As secondary antibodies, peroxidase-conjugated (Envision+) anti-rab-
bit and anti-mouse Ig reagents from Dako were used for 1h. Non-immune (Santa Cruz Bio-
technology) or pre-immune rabbit serum was used as negative controls. Reactions were
developed using diaminobenzidine (DAB) as chromogenic substrate. Images from digitalized
scans of the glass slide specimens were obtained at magnification ×20 (0.45 μm/pixel resolu-
tion) using a Hamamatsu Nanozoomer 2.0 HT. All quantifications were done using Image J.
FRET determination by FLIM measurements
Coverslips or FFPE tissue was prepared as described as above for immunofluorescence except
for the added step of quenching of autofluorescence by 15 minutes immersion in NaBH4 (1
mg/mL). FLIM was performed using time-correlated single-photon counting (TCSPC) with a
multiphoton microscope system as described previously.[19] Analysis was performed in Tri2
for time resolved analysis. To analyze FRET in tissue xenografts samples, a dedicated algorithm
was used that masks autofluorescent lifetime measurements to reveal true FRET.[20]
Enzyme-linked immunosorbent assay (ELISA)
Cells were plated in 6 well plates and incubated overnight. Supernatant was collected and EGF
and HGF ligands were measured by sandwich enzyme-linked immunosorbent assay manufac-
turer’s instructions.
Statistical analysis
Student t test for parametric data, with ANOVA comparison for more than two groups, deter-
mined statistical differences. Probability of p<0.05 was considered significant. Graphs were
prepared in Excel or in Prism (GraphPad) software.
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